Drug companies that raise prescription drug prices faster than the rate of inflation will pay rebates to the federal government or face fines.

The Centers for Medicare and Medicaid Services on Thursday released the initial guidance on the Medicare Prescription Drug Inflation Rebate Program. Drug companies will be required to pay rebates to the Medicare Trust Fund for raising prices that outpace inflation on certain drugs dispensed to people who have Medicare. 

Skip to content